Cargando…
Microencapsulated Isoniazid-Loaded Metal–Organic Frameworks for Pulmonary Administration of Antituberculosis Drugs
Tuberculosis (TB) is an infectious disease that causes a great number of deaths in the world (1.5 million people per year). This disease is currently treated by administering high doses of various oral anti-TB drugs for prolonged periods (up to 2 years). While this regimen is normally effective when...
Autores principales: | Fernández-Paz, Cristina, Fernández-Paz, Estefanía, Salcedo-Abraira, Pablo, Rojas, Sara, Barrios-Esteban, Sheila, Csaba, Noemi, Horcajada, Patricia, Remuñán-López, Carmen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8587908/ https://www.ncbi.nlm.nih.gov/pubmed/34770817 http://dx.doi.org/10.3390/molecules26216408 |
Ejemplares similares
-
Microencapsulated Chitosan-Based Nanocapsules: A New Platform for Pulmonary Gene Delivery
por: Fernández-Paz, Estefanía, et al.
Publicado: (2021) -
Antituberculosis Drug-Induced Hepatotoxicity in IranianTuberculosis Patients: Role of Isoniazid Metabolic Polymorphism
por: Sistanizad, Mohammad, et al.
Publicado: (2011) -
Antituberculosis Drugs (Rifampicin and Isoniazid) Induce Liver Injury by Regulating NLRP3 Inflammasomes
por: Su, Qiang, et al.
Publicado: (2021) -
N-Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and N-Acetyl-Isoniazid Pharmacokinetics during Antituberculosis Treatment
por: Mthiyane, Thuli, et al.
Publicado: (2020) -
Synthesis, characterization, and efficacy of antituberculosis isoniazid zinc aluminum-layered double hydroxide based nanocomposites
por: Saifullah, Bullo, et al.
Publicado: (2016)